Home›Stock Screener›Sudeep Pharma

Sudeep Pharma Share Price Today | Stock Price & Sudeep Pharma Share Screener

SUDEEPPHRM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1202.20
▼ -15.30 (-1.26%)
2026-11-18 00:00:00
Live Share Price BSE
₹1201.50
▼ -16.25 (-1.33%)
2026-11-18 00:00:00

As of November 18, 2026, the live Sudeep Pharma share price (NSE: SUDEEPPHRM) is ₹1,202.20 on NSE and ₹1,201.50 on BSE, down 1.26% from the previous close, with shares trading between ₹1,175.30 and ₹1,227.80 in today's trading session, and a 52-week range of ₹530.00–₹1,344.20. Track Sudeep Pharma market cap to gauge the company's total market size. Use the Sudeep Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sudeep Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹203 and net income of ₹52, with EBITDA of ₹79, an operating margin of 37.0% and a profit margin of 25.6%.

Sudeep Pharma Market Cap ₹13,751.50 Cr.
SUDEEPPHRM P/E Ratio (TTM) 72.90
Sudeep Pharma P/B Ratio 14.37
EPS (TTM) ₹15.50
Dividend Yield 0.12%
Debt to Equity 0.21
SUDEEPPHRM 52 Week High ₹1344.20
Sudeep Pharma 52 Week Low ₹530.00
Operating Margin 37.00%
Profit Margin 25.62%
SUDEEPPHRM Revenue (TTM) ₹203.00
EBITDA ₹79.00
Net Income ₹52.00
Total Assets ₹1,175.00
Total Equity ₹898.00

Sudeep Pharma Share Price Chart

Track the current stock price of Sudeep Pharma with an interactive chart. Analyse SUDEEPPHRM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sudeep Pharma stock quote in one place.

The quote of ₹1,202.20 sits between the 52-week low of ₹530.00 and the 52-week high of ₹1,344.20, and the latest session moved -1.26% from the previous close.

Sudeep Pharma Company Profile - Fundamental Screener

Screen Sudeep Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUDEEPPHRM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE0QPI01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE0QPI01025

Sudeep Pharma Balance Sheet Screener

Screen SUDEEPPHRM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,175, up from ₹717 in 2025.

Latest statistics put total assets at ₹1,175 and shareholder funds at ₹898, with a leverage ratio of 0.21.

Item 2026 2025 2024 2023 2022 2021 2020

Assets

Total Assets 1,175 717 514 420 344 213 131
Current Assets 0 0 0 0 0 0 0
Fixed Assets 337 189 180 158 137 68 60

Liabilities

Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 75 49 21 26 34 19 13
Non-Current Liabilities 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 898 493 356 223 163 114 81
Share Capital 11 12 1 1 1 1 1
Reserves & Surplus 872 481 355 222 162 113 80

Sudeep Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Sudeep Pharma income statement and profit fundamentals. Analyze SUDEEPPHRM quarterly results. Sudeep Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹203 and net profit was ₹52, equal to earnings per unit of ₹4.59, at an operating margin of 37%.

In that period expenses were ₹124, interest cost ₹3 and tax ₹19. The next period listed, 2026-Jun, shows revenue of ₹164 and net profit of ₹41.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun

Revenue and Expenses

Revenue 203 164 189 179 173 130 161 118 151 81
Expenses 124 103 120 112 107 81 99 76 85 52

Operating Costs and Margins

EBITDA 79 60 69 67 66 49 63 42 65 30
Operating Profit % 37.00% 35.00% 34.00% 35.00% 34.00% 35.00% 37.00% 34.00% 43.00% 35.00%
Depreciation 5 4 4 4 4 3 3 3 3 3
Interest 3 2 2 1 2 2 2 1 1 2

Profit and Earnings

Profit Before Tax 71 54 63 62 60 44 58 38 62 26
Tax 19 14 14 14 13 13 14 9 13 9
Net Profit 52 41 49 48 47 31 44 29 49 17
EPS 4.59 3.59 4.38 4.29 4.20 2.84 4.07 2.65 4.49 4.49

Sudeep Pharma Cash Flow Screener - Liquidity Fundamentals

Screen SUDEEPPHRM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹70, and net cash flow was an outflow of ₹10.

Over the same period, investing activities used ₹327 and financing activities provided ₹247.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March

Cash from Operations and Investing

Operating Activities 70 49 66 48 -3 35 10
Investing Activities -327 -79 -49 -50 -38 -40 -23

Financing and Net Cash

Financing Activities 247 53 -13 -10 51 13 12
Net Cash Flow -10 23 4 -11 10 8 0

Sudeep Pharma Shareholding Pattern Screener

See Sudeep Pharma shareholding pattern with promoter, FII, and DII holdings. Check Sudeep Pharma promoter holding and ownership changes for SUDEEPPHRM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 76.15%, foreign institutions 2.93%, domestic institutions 14.05% and the public 5.43%, spread across 40,465 shareholders.

The shareholder count was 40,465 in 2026-Sept, compared with 35,695 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Nov 2025-Jun

Promoter Holding

Promoter Holding 76.15% 76.15% 76.15% 76.15% 89.36% 91.07%

Institutional Investors

FII Holding 2.93% 1.81% 1.55% 1.67% 0.00% 0.00%
DII Holding 14.05% 15.65% 18.11% 17.60% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 5.43% 4.89% 3.11% 3.27% 0.00% 0.00%
Other Holding 1.44% 1.50% 1.07% 1.31% 10.64% 8.93%
Shareholder Count 40,465 35,695 36,503 43,599 26 16

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sudeep Pharma. Sudeep Pharma dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Sudeep Pharma.

Sudeep Pharma Stock Index Membership - Nifty & Sensex

See which indices include Sudeep Pharma stock. Check SUDEEPPHRM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Sudeep Pharma is not part of any tracked indices.
Only major market indices are tracked in our system.

Sudeep Pharma Market Events Screener - Corporate Actions

Get Sudeep Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sudeep Pharma stock events that may affect SUDEEPPHRM share price, along with derivatives, futures and options activity and sector gainers.

7 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 28, 2026, with a record date of October 28, 2026.

It is followed by Annual General Meeting dated August 4, 2026 and Quarterly Result Announcement dated August 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-28 2026-10-28 Quarterly Result Announcement NA 1.85%
2026-08-04 2026-08-04 Annual General Meeting NA 8.26%
2026-08-04 2026-08-04 Quarterly Result Announcement NA 5.07%
2026-07-23 2026-07-23 Dividend ₹ 1.50 /share 30.91%
2026-05-21 2026-05-21 Quarterly Result Announcement NA 2.43%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 4.11%
2025-12-19 2025-12-19 Quarterly Result Announcement NA -3.62%

Sudeep Pharma Competitors Screener - Peer Stocks Comparison

Screen SUDEEPPHRM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,998 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 84.70 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 94.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.90 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 42.00 35,059 3.90% 4,158 71.26
Cipla 112,131 39.20 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.50 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.90 34,145 5.56% 3,503 60.39
Lupin 89,172 17.10 29,039 26.75% 5,356 39.39

Sudeep Pharma Company Announcements - News & Reports Screener

Screen SUDEEPPHRM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 3, 2026.

The next most recent announcements are dated October 29, 2026 and October 29, 2026.

Date Update Actions
2026-11-03 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-10-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-29 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-28 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-28 Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026 -
2026-10-28 Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th October 2026 -
2026-10-26 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-21 Board Meeting Intimation for Adoption And Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th September 2026 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-05 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-25 Closure of Trading Window -
2026-09-23 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-11 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-06 General Update -
2026-08-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-08-05 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,202.20, within a 52-week range of ₹530.00 to ₹1,344.20. The P/E ratio is 72.90 and the P/B ratio is 14.37, with earnings per unit of ₹15.50. Market capitalisation stands at ₹13,751.50 Cr and the dividend yield is 0.12%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 7 balance sheet periods, 10 income statement periods, 7 cash flow years and 6 shareholding periods. Information is provided for research and is not investment advice.